Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
Editorial Group: Cochrane Stroke Group
Published Online: 11 JUL 2012
Assessed as up-to-date: 29 NOV 2011
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Li J, Liu M, Zhang S, Hao Z, Zhang C, Zhang J. Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD009938. DOI: 10.1002/14651858.CD009938.
- Publication Status: New
- Published Online: 11 JUL 2012
This is the protocol for a review and there is no abstract. The objectives are as follows:
The first objective is to compare the safety and efficacy of transcatheter device closure (TDC) with best medical therapy alone for the prevention of recurrent stroke (fatal or not) or TIA in patients with PFO and a history of cryptogenic stroke or TIA. The second objective is to identify specific subgroups of patients most likely to benefit from closure for secondary prevention and to assess the cost-effectiveness of this strategy, if possible.